Literature DB >> 2754276

Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles.

W Seibel1, J P Sundberg, L J Lesko, J J Sauk, L B McCleary, T M Hassell.   

Abstract

All twelve Beagle dogs undergoing long-term therapy (26 weeks) with the immunosuppressive drug cyclosporine-A (30 mg/kg), developed cutaneous papillomatous hyperplasia. By week 7 all dogs developed generalized lesions distributed over the entire body. These occurred as irregular, oval, sessile, unpigmented, firm masses. The incidence and severity of the skin lesions varied among dogs and anatomic site, with no correlation to the blood level of cyclosporine. Microscopic analysis revealed that the epidermis formed short papillary folds on broad fibrovascular stalks and was hyperkeratotic and acanthotic. Mild hyperplasia of hair follicles and sebaceous glands was also evident. A mild diffuse infiltrate of lymphocytes and plasma cells was present in the papillary dermis. No histopathologic changes typical of papillomavirus infection were identified, nor were papillomavirus group-specific antigens or viral DNA detected. Other cutaneous side effects included hyperkeratosis of footpads, increased growth of hair and nails, and hyperkeratinization of the haired skin of the prepuce. All cutaneous lesions regressed spontaneously within 8 weeks following termination of cyclosporine administration. The hyperplastic lesions may have resulted from the action of cyclosporine via the T-lymphocyte system. Conversely a direct action of this drug on epithelial cells may have stimulated proliferation and keratinization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754276     DOI: 10.1111/1523-1747.ep12277577

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs.

Authors:  Michael H Goldschmidt; Jeffrey S Kennedy; Douglas R Kennedy; Hang Yuan; David E Holt; Margret L Casal; Anne M Traas; Elizabeth A Mauldin; Peter F Moore; Paula S Henthorn; Brian J Hartnett; Kenneth I Weinberg; Richard Schlegel; Peter J Felsburg
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.

Authors:  N D Christensen; R Han; N M Cladel; M D Pickel
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 3.  Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.

Authors:  Tim Nuttall; Douglas Reece; Elizabeth Roberts
Journal:  Vet Rec       Date:  2014-03       Impact factor: 2.695

4.  Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?

Authors:  Wendy R Kam; Yang Liu; Juan Ding; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

5.  Glucocorticosteroids and ciclosporin do not significantly impact canine cutaneous microbiota.

Authors:  Giovanni Widmer; Lluís Ferrer; Claude Favrot; Judy Paps; Kevin Huynh; Thierry Olivry
Journal:  BMC Vet Res       Date:  2018-02-23       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.